home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

78.75 +5.48 (+7.47%)

Streaming Delayed Price Updated: 1:02 PM EDT, Jun 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

May 23, 2023

From The Schall Law Firm

Via Business Wire

PTC Therapeutics Takes Investors On A Ride With A Failed Study, Scrapped Programs, Ousted CFO ↗

May 23, 2023

PTC announced a barrage of news, starting with a failed Phase 3 study.

Via Investor's Business Daily

Chart Of The Day: PTC Therapeutics ↗

May 18, 2023

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for patients with rare disorders.

Via Talk Markets

Palo Alto Networks To Rally Around 21%? Here Are 10 Other Analyst Forecasts For Thursday ↗

May 18, 2023

Needham raised the price target for Dynatrace, Inc. (NYSE: DT) from $52 to $56. Needham analyst James Ricchiuti maintained a Buy rating. Dynatrace shares gained 1.9% to $47.95 in pre-market trading.

Via Benzinga

The Latest Analyst Ratings for PTC Therapeutics ↗

May 08, 2023

Via Benzinga

PTC Therapeutics's Return On Capital Employed Insights ↗

May 04, 2023

Via Benzinga

Analyst Expectations for PTC Therapeutics's Future ↗

April 18, 2023

Via Benzinga

Where PTC Therapeutics Stands With Analysts ↗

March 17, 2023

Via Benzinga

Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals ↗

May 17, 2023

The company is working on a treatment for PKU, a disorder that can lead to intellectual disabilities.

Via Investor's Business Daily

Why did Sarepta Therapeutics Stock Plummet?

March 21, 2023

SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.

Via MarketBeat

7 Nasdaq Stocks to Sell Before They Plunge in 2023 ↗

December 05, 2022

While loyalty may be a positive trait in most circumstances, when it comes to Nasdaq stocks to sell, you got to look out for number one.

Via InvestorPlace

PTC Therapeutics's Return On Capital Employed Overview ↗

November 02, 2022

According to Benzinga Pro data, during Q3, PTC Therapeutics (NASDAQ:PTCT) posted sales of $217.13 million. Earnings were up 28.12%, but PTC Therapeutics still reported an overall loss of $109.31...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 28, 2022

Gainers Nuvalent (NASDAQ:NUVL) stock increased by 15.9% to $25.5 during Friday's pre-market session. The company's market cap stands at $1.2 billion.

Via Benzinga

Reaction Is Overdone For PTC Therapeutics Pausing Huntington Trial Enrollment, Analyst Says ↗

October 19, 2022

Via Benzinga

PTC Therapeutics Pauses Enrollment In Huntington's Candidate Trial In US ↗

October 19, 2022

Via Benzinga

Earnings Scheduled For April 27, 2023 ↗

April 27, 2023

Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter.

Via Benzinga

Looking Into PTC Therapeutics's Return On Capital Employed ↗

February 22, 2023

Via Benzinga

Earnings Outlook For PTC Therapeutics ↗

February 20, 2023

Via Benzinga

Expert Ratings for PTC Therapeutics ↗

December 14, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023 ↗

March 17, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 19, 2022

Gainers Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 74.8% to $0.17 during Wednesday's pre-market session. The company's market cap stands at $14.1 million.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 18, 2022

Gainers

Via Benzinga

What 5 Analyst Ratings Have To Say About PTC Therapeutics ↗

October 17, 2022

Within the last quarter, PTC Therapeutics (NASDAQ:PTCT) has observed the following analyst ratings:

Via Benzinga

Expert Ratings for PTC Therapeutics ↗

October 17, 2022

Analysts have provided the following ratings for PTC Therapeutics (NASDAQ:PTCT) within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗

December 14, 2022

Via Benzinga

PTC Therapeutics Gets $1B Funding From Blackstone, Shares Fall ↗

October 28, 2022

Via Benzinga

Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday ↗

October 31, 2022

Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday.

Via Benzinga

Marten Transport, Silvergate Capital And Some Other Big Stocks Moving Lower On Tuesday ↗

October 18, 2022

U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Why Edwards Lifesciences Shares Are Trading Lower By Around 17%? Here Are 47 Stocks Moving In Friday's Mid-Day Session ↗

October 28, 2022

Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) surged 179% to $3.6301.

Via Benzinga

Earnings Scheduled For October 27, 2022 ↗

October 27, 2022

Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com